| Human immunodeficiency virus I infection
Juluca vs Norvir
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Juluca vs Norvir with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNorvir has a higher rate of injection site reactions vs Juluca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Norvir but not Juluca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Juluca
Norvir
At A Glance
Oral
Once daily
INSTI/NNRTI combination
Oral
Twice daily
HIV protease inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet (dolutegravir 50 mg/rilpivirine 25 mg) orally once daily with a meal; if coadministered with rifabutin, take an additional rilpivirine 25-mg tablet with JULUCA once daily with a meal for the duration of rifabutin coadministration.
Human immunodeficiency virus I infection (Adults) 600 mg twice daily by mouth with meals; initiate at 300 mg twice daily and increase by 100 mg q2-3 days to minimize adverse events.
Human immunodeficiency virus I infection (Pediatrics >1 month) 350-400 mg/m2 twice daily by mouth with meals, not to exceed 600 mg twice daily; initiate at 250 mg/m2 twice daily and increase by 50 mg/m2 q2-3 days.
Contraindications
- Previous hypersensitivity reaction to dolutegravir or rilpivirine
- Coadministration with dofetilide
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with systemic dexamethasone (more than a single-dose treatment)
- Coadministration with St John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
- Known hypersensitivity (e.g., TEN or Stevens-Johnson syndrome) to ritonavir or any excipient
- Co-administration with drugs highly dependent on CYP3A for clearance with potential for serious or life-threatening reactions: alfuzosin, ranolazine, amiodarone, dronedarone, flecainide, propafenone, quinidine, voriconazole, colchicine (renal/hepatic impairment), lurasidone, pimozide, dihydroergotamine, ergotamine, methylergonovine, cisapride, lovastatin, simvastatin, lomitapide, sildenafil (Revatio for PAH), triazolam, oral midazolam
- Co-administration with potent CYP3A inducers associated with potential loss of virologic response: apalutamide, St. John's Wort (hypericum perforatum)
Adverse Reactions
Most common (>=2%) Diarrhea, headache, nausea
Serious Depressive disorders including suicidal ideation, hepatotoxicity, skin and hypersensitivity reactions
Postmarketing Acute liver failure, hepatotoxicity, weight increase, arthralgia, myalgia, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Most common (>=1%) Diarrhea, nausea, vomiting, abdominal pain, paresthesia (including oral), rash, fatigue/asthenia, dysgeusia, coughing, arthralgia, back pain, dizziness, pruritus, myalgia, flushing, hypertriglyceridemia, peripheral neuropathy, oropharyngeal pain
Serious Hepatotoxicity, pancreatitis, allergic reactions/hypersensitivity
Postmarketing Dehydration, AV block (first-, second-, third-degree), right bundle branch block, Cushing's syndrome, adrenal suppression, seizure, nephrolithiasis, toxic epidermal necrolysis
Pharmacology
JULUCA is a fixed-dose combination of dolutegravir, an integrase strand transfer inhibitor (INSTI) that blocks the strand transfer step of retroviral DNA integration essential for HIV replication, and rilpivirine, a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) that non-competitively inhibits HIV-1 reverse transcriptase without inhibiting human cellular DNA polymerases alpha, beta, or gamma.
Ritonavir is a peptidomimetic inhibitor of the HIV-1 protease that renders the enzyme incapable of processing the Gag-Pol polyprotein precursor, leading to production of non-infectious immature HIV particles; it also potently inhibits CYP3A and, to a lesser extent, CYP2D6, significantly affecting plasma concentrations of many co-administered drugs.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Juluca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (1/12) · Qty limit (11/12)
Norvir
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Juluca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Norvir
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Juluca
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Norvir
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JulucaView full Juluca profile
NorvirView full Norvir profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.